Report on the risk assessment of 1-(3-chlorophenyl)-2-(methylamino)propan-1-one (3-chloromethcathinone, 3-CMC) in accordance with Article 5c of Regulation (EC) No 1920/2006 (as amended)
Introduction
This publication presents the data and findings of the risk assessment on 1-(3-chlorophenyl)-2-(methylamino)propan-1-one (3-chloromethcathinone, 3-CMC), carried out by the extended Scientific Committee of the EMCDDA on 19 November 2021. On the basis of the Risk Assessment Report, on 18 March 2022, the Commission decided that 3-CMC should be included in the definition of 'drug', in the Annex to Framework Decision 2004/757/JHA.
Download as PDF
Table of contents
- Acknowledgements
- Foreword
- EMCDDA Initial Report on 1-(3-chlorophenyl)-2-(methylamino)propan-1-one (3-chloromethcathinone, 3-CMC)
- Risk assessment report on a new psychoactive substance: 1-(3-chlorophenyl)-2-(methylamino)propan-1-one (3-chloromethcathinone, 3-CMC)
- Annex 1: Technical report on the new psychoactive substance 1-(3-chlorophenyl)-2-(methylamino)propan-1-one (3-chloromethcathinone, 3-CMC)
- Annex 2: Participants of the risk assessment meeting, 19 November 2021
Issue:
35
Pages:
90
Price:
free
ISBN:
978-92-9497-703-8
ISSN:
1725-4493
Pub. DOI:
10.2810/671114
Catalog Number:
TD-AK-22-003-EN-N
Main subject
Target audience